Monopar Therapeutics Quarterly Debt-to-equity in % from Q3 2018 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Monopar Therapeutics quarterly Debt-to-equity history and growth rate from Q3 2018 to Q2 2024.
Monopar Therapeutics Debt-to-equity for the quarter ending June 30, 2024 was 24.3 %, a 8.51% decline year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	24.3	-2.26	-8.51%	Jun 30, 2024
Q1 2024	27.9	+5.8	+26.2%	Mar 31, 2024
Q4 2023	31.5	+16	+103%	Dec 31, 2023
Q3 2023	31.4	+20.5	+189%	Sep 30, 2023
Q2 2023	26.6	+18	+210%	Jun 30, 2023
Q1 2023	22.1	+15.9	+254%	Mar 31, 2023
Q4 2022	15.5			Dec 31, 2022
Q3 2022	10.9			Sep 30, 2022
Q2 2022	8.56			Jun 30, 2022
Q1 2022	6.24			Mar 31, 2022
Q4 2020	5.08	-2.93	-36.6%	Dec 31, 2020
Q3 2020	4.54	-4.07	-47.3%	Sep 30, 2020
Q2 2020	5.5	-1.43	-20.6%	Jun 30, 2020
Q1 2020	6.1	+0.41	+7.21%	Mar 31, 2020
Q4 2019	8.01	+3.8	+90.3%	Dec 31, 2019
Q3 2019	8.61	+4.99	+138%	Sep 30, 2019
Q2 2019	6.93			Jun 30, 2019
Q1 2019	5.69			Mar 31, 2019
Q4 2018	4.21			Dec 31, 2018
Q3 2018	3.62			Sep 30, 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.